Milatuzumab, previously known as MEDI-115, represents a novel approach targeting human leukemia-lymphoma antigen 1 (hLL1), also identifiable by the identifier 899796-83-9. This antibody exhibits selective affinity to hLL1, a molecule frequently overexpressed in several cancers of the blood. The creation surrounding Milatuzumab has focused on its… Read More

The debut of troglitazone, a potent antidiabetic agent, marked a notable chapter in the management of type 2 diabetes. However, its removal from the market due to substantial hepatotoxicity spurred extensive investigation into related thiazolidinediones. Subsequently pioglitazone and rosiglitazone emerged, offering analogous mechanisms of action… Read More